Chronic Myeloid Leukemia

CHRONIC MYELOID LEUKEMIA ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends

The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
Biosimilars in Cancer Care: Insights From 2020 and Expectations for 2021

Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
NCI-MATCH Trial Identifies Actionable Alterations in More Than One-Third of Patients With Cancer

Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
Targeted Therapies, Immunotherapies, Immunomodulators: A Quick Guide to Cancer Therapy Descriptions

Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
British Society for Haematology Guideline Update for the Diagnosis and Management of Chronic Myeloid Leukemia

The British Society for Haematology has published updated guidelines for the diagnosis and management of chronic myeloid leukemia in adults and children.

CHRONIC MYELOID LEUKEMIA NEWS

A blood smear of chronic myeloid leukemia cells.

Dasatinib, Nilotinib Effective Second-Line Therapy for Chronic Myeloid Leukemia

April 8, 2021

The Leukemia & Lymphoma Society partnered with Sutro Biopharma to test the safety of the investigati

BCR-ABL1 Kinetics Associated With Long-Term TFR Status in Patients With Chronic Myeloid Leukemia

March 31, 2021

Checking a patient's temperature.

Case Study Shows Potential Protective Effect of TKI Therapy for Chronic Myeloid Leukemia

March 26, 2021

Total XV protocol significantly improves survival in older adolescents with leukemia

Molecular Response Maintained With Intermittent Tyrosine Kinase Inhibitor Regimen in Patients With CML

March 10, 2021

Patients with newly diagnosed chronic myeloid leukemia in chronic phase should be considered before

Anti-Emetic Drug Effectively Blocks CD93 Signaling in Preclinical Evaluations, Suggesting Suitability in CML

February 2, 2021

Next post in Chronic Myeloid Leukemia

The Leukemia & Lymphoma Society partnered with Sutro Biopharma to test the safety of the investigati

BCR-ABL1 Kinetics Associated With Long-Term TFR Status in Patients With Chronic Myeloid Leukemia